These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25221585)

  • 21. Thrombolytic therapy in experimental embolic stroke.
    Overgaard K
    Cerebrovasc Brain Metab Rev; 1994; 6(3):257-86. PubMed ID: 7811566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a novel marine natural product: pyrano indolone alkaloid fibrinolytic compound on thrombolysis and hemorrhagic activities in vitro and in vivo.
    Yan T; Wu W; Su T; Chen J; Zhu Q; Zhang C; Wang X; Bao B
    Arch Pharm Res; 2015 Aug; 38(8):1530-40. PubMed ID: 25475097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic ultrasound in ischemic stroke treatment: experimental evidence.
    Daffertshofer M; Fatar M
    Eur J Ultrasound; 2002 Nov; 16(1-2):121-30. PubMed ID: 12470857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of safety and efficacy of the various thrombolytic agents.
    Ouriel K
    Rev Cardiovasc Med; 2002; 3 Suppl 2():S17-24. PubMed ID: 12556739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy.
    Marder VJ
    Am J Med; 1987 Aug; 83(2A):15-9. PubMed ID: 3115098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombolysis for acute ischaemic stroke.
    Wardlaw JM; Murray V; Berge E; Del Zoppo GJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD000213. PubMed ID: 19821269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
    McCarthy JR; Sazonova IY; Erdem SS; Hara T; Thompson BD; Patel P; Botnaru I; Lin CP; Reed GL; Weissleder R; Jaffer FA
    Nanomedicine (Lond); 2012 Jul; 7(7):1017-28. PubMed ID: 22348271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet membrane-functionalized nanoparticles with improved targeting ability and lower hemorrhagic risk for thrombolysis therapy.
    Wang S; Wang R; Meng N; Guo H; Wu S; Wang X; Li J; Wang H; Jiang K; Xie C; Liu Y; Wang H; Lu W
    J Control Release; 2020 Dec; 328():78-86. PubMed ID: 32853731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent progress in developing of thrombolytic agents for ischemic stroke].
    Xu Y; Chen S; Chen D; Peng S; Cheng Y; Li J; Li Y; Jiang L; Yuan C; Huang M
    Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):2029-2039. PubMed ID: 33169568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of different doses of alteplase thrombolysis on acute ischemic stroke in patients.
    Xu H
    Pak J Pharm Sci; 2019 Sep; 32(5(Special)):2465-2469. PubMed ID: 31894036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous thrombolytic therapy in acute stroke.
    Tong DC; Yenari MA; Albers GW
    Vasc Med; 1997; 2(1):51-60. PubMed ID: 9546949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical update on thrombolytic use in pulmonary embolism: A focus on intermediate-risk patients.
    Eberle H; Lyn R; Knight T; Hodge E; Daley M
    Am J Health Syst Pharm; 2018 Sep; 75(17):1275-1285. PubMed ID: 29895520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction.
    Cannon CP
    J Am Coll Cardiol; 1999 Nov; 34(5):1395-402. PubMed ID: 10551684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct Imaging of Cerebral Thromboemboli Using Computed Tomography and Fibrin-targeted Gold Nanoparticles.
    Kim JY; Ryu JH; Schellingerhout D; Sun IC; Lee SK; Jeon S; Kim J; Kwon IC; Nahrendorf M; Ahn CH; Kim K; Kim DE
    Theranostics; 2015; 5(10):1098-114. PubMed ID: 26199648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
    Absar S; Nahar K; Kwon YM; Ahsan F
    Pharm Res; 2013 Jun; 30(6):1663-76. PubMed ID: 23468049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Thrombolytics and neuroprotective agents in the treatment of the patient with an acute cerebrovascular ischemic accident].
    Yepes MS
    Rev Neurol; 2001 Feb 1-15; 32(3):259-66. PubMed ID: 11310282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of thrombolytic therapy using reteplase in cases with acute ST-segment elevation myocardial infarction: results from a multicenter clinical trial].
    Liu XY; Zhang Y; Li MW; Wang XP; Qi DD; Hao PY; Zhang H; Cheng QQ; Zhao LS; Gao CY; Hu DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Sep; 44(9):766-770. PubMed ID: 27667274
    [No Abstract]   [Full Text] [Related]  

  • 39. Life-saving systemic thrombolysis in a patient with massive pulmonary embolism and a recent hemorrhagic cerebrovascular accident.
    Bottinor W; Turlington J; Raza S; Roberts CS; Malhotra R; Jovin IS; Abbate A
    Tex Heart Inst J; 2014 Apr; 41(2):174-6. PubMed ID: 24808778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
    Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
    Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.